When a company such as TransCode Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the RNAZ split history from start to finish, an original position size of 1000 shares would have turned into 1.25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TransCode Therapeutics shares, starting with a $10,000 purchase of RNAZ, presented on a split-history-adjusted basis factoring in the complete RNAZ split history.